metricas
covid
Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patie...
Journal Information
Vol. 41. Issue 1.
Pages 3-10 (January - February 2022)
Share
Share
Download PDF
More article options
Visits
4
Vol. 41. Issue 1.
Pages 3-10 (January - February 2022)
Original Article
The prognostic role of baseline 18F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy
El papel pronóstico del SUVmáx basal y cambio del SUVmáx en la PET/TC con 18F-FDG en pacientes con cáncer de mama con ganglios positivos que reciben quimioterapia neoadyuvante
Visits
4
Canan Cana, Nadiye Akdenizb, Halil Kömeka,
Corresponding author
halilkomek@gmail.com

Corresponding author.
, Cihan Gündoğana, Zuhat Urakçıc, Abdurrahman Işıkdoğanc
a Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital, Diyarbakir, Turkey
b Department of Medical Oncology, Adiyaman Training and Research Hospital, Adiyaman, Turkey
c Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (5)
Table 1. Patient and tumor characteristics.
Table 2. Comparison of PET/CT parameters and histopathological features with mortality and Recurrence.
Table 3. Univariate analysis for disease free survival.
Table 4. Univariate analysis for overall survival.
Table 5. Multivariant analysis for diseases-free survial and overall survival.
Show moreShow less
Abstract
Objective

This study aimed to determine the prognostic role of baseline maximum standardized uptake value (SUVmax) obtained by pretreatment PET/CT and the change in SUVmax (ΔSUVmax [%]) in patients with axillary lymph node–positive breast cancer receiving neoadjuvant chemotherapy (NAC).

Methods

One hundred and eighty patients with baseline SUVmax and 121 patients with SUVmax measurement after treatment were evaluated in the study. The baseline SUVmax value of the breast (SUVmaxBI) and axilla (SUVmaxAI) and the change in the SUVmax of the breast (ΔSUVmaxB) and axilla (ΔSUVmaxA) were measured. The optimal cut-off value of SUVmax and ΔSUVmax were determined by ROC curve analysis. Disease-free survival (DFS) and overall survival (OS) were calculated using Kaplan–Meier curves.

Results

ΔSUVmaxB, pCRB, pCRA, and pCR parameters were found to be associated with relapse (P < .001, P = .033, P = .016, and P = .013, respectively). ΔSUVmaxB and SUVmaxAI were associated with mortality (P = .001 and P = .006, respectively). Multiple Cox regression analyses revealed that ΔSUVmaxB value was an independent prognostic factor for relapse and mortality (P = .013 and P = .010, respectively).

Conclusion

The results showed that ΔSUVmaxB was an independent prognostic factor for relapse and mortality in patients with axillary lymph node–positive breast cancer who received NAC.

Keywords:
Breast cancer
18FDG PET/CT
Neoadjuvant chemotherapy
SUVmax change
Prediction response
Prognosis
Resumen
Objetivo

En este estudio, se tuvo como objetivo determinar el papel pronóstico del valor de captación máximo estandarizado (SUVmáx) basal obtenido por PET/TC antes del tratamiento, y el cambio en el SUVmáx (ΔSUVmáx [%]) en pacientes con cáncer de mama con ganglios linfáticos axilares positivos que habían recibido quimioterapia neoadyuvante (NAC).

Métodos

Se evaluaron en el estudio 180 pacientes con SUVmáx basal y 121 pacientes con medición de SUVmáx después del tratamiento. Se midieron el valor de SUVmáx inicial de la mama (SUVmáxBI) y axila (SUVmáxAI), y el cambio en el SUVmáx de la mama (ΔSUVmáxB) y axila (ΔSUVmáxA). El valor de corte óptimo de SUVmáx y ΔSUVmáx se determinó mediante el análisis de la curva ROC. La supervivencia libre de enfermedad (SLE) y la supervivencia global (SG) se calcularon mediante curvas de Kaplan-Meier.

Resultados

Se encontró que los parámetros ΔSUVmáxB, pCRB, pCRA y pCR se asociaron con la recaída (P < .001, P = .033, P = .016 y P = .013, respectivamente). ΔSUVmáxB y SUVmáxAI se asociaron con la mortalidad (P = ,001 y P = ,006, respectivamente). El análisis de regresión de Cox múltiple reveló que el valor de ΔSUVmáxB era un factor pronóstico independiente para la recaída y la mortalidad (P = ,013 y P = ,010, respectivamente).

Conclusión

Los resultados muestran que ΔSUVmáxB es un factor pronóstico independiente de recaída y mortalidad en pacientes con cáncer de mama con ganglios linfáticos axilares positivos que recibieron NAC.

Palabras clave:
Cáncer de mama
18FDG PET/TC
Quimioterapia neoadyuvante
Cambio de SUVmáx
Predicción de respuesta
Pronóstico

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos